Self-concept before and after two years of growth hormone treatment in intrauterine growth-retarded children.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

All children had a birth length below the 3rd percentile, and did not show catch-up growth (current height < P3).

The researchers compared the self-concept measures (Self-Perception Profile for Children; SPPC) of the IUGR group with similar measures of a Dutch school sample.

Who Took Part

The abstract describes 25 children taking part.

By PubMed's age tags, the people studied were children, both men and women.

How the Study Was Run

The researchers set it up as a randomized and double-blind study.

The children were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Blinding on both sides kept the children and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

What Was Measured

The researchers compared the self-concept measures (Self-Perception Profile for Children; SPPC) of the IUGR group with similar measures of a Dutch school sample.

The subject headings attached to it are Cohort Studies, Fetal Growth Retardation, Human Growth Hormone and Self Concept.

What This Means in Plain Language

The paper is a randomized and double-blind study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 25 children.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1996 (Hormone research), a journal based in Switzerland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.